ERAS-601
N/A
Report date: 2025/08/01 20:01:42
NME
Base Information
Drug NameERAS-601
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNiKang Therapeutics Inc
China Registration ClassN/A
Develop Information
Active CompaniesMemorial Sloan Kettering Cancer CenterErasca Inc
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A